Novartis AG’s Clozaril (clozapine), which was the first atypical antipsychotic approved by the US Food and Drug Administration (FDA), may soon become the first and only drug indicated in the US for the treatment of suicidal behavior.
Seven out of nine members of an FDA advisory committee voted on Monday in favor of recommending that the agency grant Clozaril a supplementary indication for the treatment of emergent suicidal behavior in patients with schizophrenia or schizoaffective disorder.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!